Dose Escalation of IPI-493 in Hematologic Malignancies
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose
(MTD) and schedule of IPI-493 in patients with hematologic malignancies.